CDKN2A and Barrett esophagus: In the progression risk analysis, aberrant p16 showed a 3.5 RR but not significantly associated with LGD progressor cohorts, while it is significantly associated with BE-IND progressors in a 4.4 ( 95% CI, 2.5-7.6).